Pharmaceutical News

RSS

Med14 protein drives GLP-1 benefits in pancreatic beta cells

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health.

6 Mar 2026

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Repurposed kidney drug finerenone shows promise in treating premature ovarian insufficiency

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age.

5 Mar 2026

High use of anticholinergic drugs linked to increased cardiovascular disease risk

People who use drugs with anticholinergic effects, including certain antidepressants, drugs for urinary incontinence and common antihistamines, are at higher risk of developing cardiovascular disease.

5 Mar 2026

GLP-1 drugs may be effective at treating and preventing substance use disorders

Researchers at Washington University School of Medicine in St. Louis show in a new study that GLP-1 medications may be effective at treating and preventing substance use disorders across all major addictive substances studied, suggesting these drugs target a common biological pathway underlying addiction.

4 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Weight-loss drugs may reduce heart damage after heart attack

Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London.

2 Mar 2026

Unprescribed Adderall causes significant cardiovascular effects in young adults

A Mayo Clinic study found that a single 25 mg dose of a combination of amphetamine-dextroamphetamine salts (Adderall) can have measurable cardiovascular effects in healthy young adults.

2 Mar 2026

Acoziborole receives positive opinion for single-dose sleeping sickness treatment

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion to Acoziborole Winthrop (acoziborole) as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults as well as in adolescents 12 years and older weighing at least 40 kilograms.

27 Feb 2026

He needs an expensive drug. A copay card helped — until it didn’t.

Over the course of 2025, Jayant Mishra of Mission Viejo, California, progressively developed scaly, itchy red patches on his skin. Then came the pain and swelling in the joints of his hands, making it difficult to do his work at a bank.

27 Feb 2026

Daily aspirin not reliable for preventing bowel cancer

Daily aspirin use does not offer a quick or reliable way to prevent bowel cancer in the general population and carries immediate risks of serious bleeding, a new Cochrane review finds.

25 Feb 2026

Study finds sharp drop in benzodiazepine use among older adults

Benzodiazepine treatment declined among U.S. adults between 2018 and 2022, with the steepest drop among adults ages 56 and older, according to a new study by researchers at the Columbia University Mailman School of Public Health and Columbia University Irving Medical Center.

25 Feb 2026

Opioids offer limited short-term relief for acute pain

The world's largest review of opioid pain relievers prescribed for acute pain found these medicines provide only small, short-term relief for some acute conditions and are ineffective for some others.

25 Feb 2026

Comparing denture cleansers for effectiveness against Candida biofilms

Candida species, particularly Candida albicans, are major contributors to denture-induced stomatitis because of their ability to form biofilms on removable dental prostheses.

24 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

New antimicrobial strategies show how science is tackling rising drug resistance

This narrative review in the British Journal of Biomedical Science examines emerging and recently approved therapeutic strategies to combat antimicrobial resistance, spanning new antibiotics, microbiome interventions, natural products, predatory bacteria, vaccines, and advanced technologies. It highlights both promising innovations and the urgent need for sustained global investment as many approaches remain in early development.

24 Feb 2026